LVTX
LAVA Therapeutics N.V.1.7400
+0.0000+0%
Nov 20, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
45.77MP/E (TTM)
-Basic EPS (TTM)
-0.87Dividend Yield
0%Recent Filings
8-K
XOMA completes LAVA takeover
XOMA Royalty Corporation completed its takeover of LAVA Therapeutics on November 13, 2025, accepting 87% of shares at $1.04 each plus a CVR; a subsequent period pushed tenders to 91.1% by November 20. Nasdaq suspended trading November 21, with delisting via Form 25 and Form 15 planned for December 1. Executives Hurly and Powell exited with severance. Going private now.
8-K
Tender offer closes; control shifts
XOMA Royalty closed its tender offer for LAVA Therapeutics on November 13, 2025, accepting 22,877,463 shares—87% of outstanding—for $1.04 per share plus a CVR. Control shifted; most board directors departed, replaced by XOMA appointees Owen Hughes and others. Nasdaq delisting looms post-subsequent offer ending November 20. Going private now.
8-K
Shareholders greenlight merger
LAVA Therapeutics shareholders overwhelmingly approved a Dutch downstream merger with New Topco at the November 7, 2025 EGM, with 63.45% quorum and near-unanimous support for the merger and share exchanges favoring XOMA Royalty Corp. Directors Owen Hughes, Thomas Burns, Bradley Sitko, and Maricel Montano received conditional appointments. Board got discharge. Merger advances XOMA tender offer.
10-Q
Q3 FY2025 results
LAVA Therapeutics posted a narrower Q3 operating loss of $7.6M, down 33% y/y from $11.3M, as R&D costs plunged 73% to $2.2M amid program discontinuations, while G&A rose 73% to $5.3M on XOMA deal fees. Net loss improved to $7.2M from $12.3M y/y, with EPS at -$0.27 versus -$0.46; YTD net loss narrowed to $19.3M from $21.2M, EPS -$0.72 from -$0.79, reconciling to 26.9M diluted shares. Cash swelled to $49.7M, bolstered by $40.1M in investment maturities, with no debt after a $5.2M waiver. The pending XOMA acquisition, amended October 17 for $1.04/share plus CVRs tied to net cash and milestones, eyes Q4 close. Restructuring slashed headcount 71%, yielding $3.9M in charges. Deal failure risks liquidation.
8-K
LAVA amends acquisition deal
LAVA Therapeutics amended its share purchase agreement with XOMA Royalty on October 17, 2025, setting a fixed $1.04 cash per share for tendering shareholders, down from $1.16-$1.24, plus a non-transferable CVR tied to net proceeds from partnerships with Pfizer and Johnson & Johnson, asset dispositions, and a $6.33 million tax reserve resolution. The tender offer now expires November 12, 2025, with minimum closing net cash lowered to $24.5 million amid liability estimates. Deal closure hinges on 80% share tender and EGM approval November 7. CVRs may yield nothing if milestones falter.
IPO
Employees
Sector
Industry
BNTX
BioNTech SE
92.23-1.52
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CMPX
Compass Therapeutics, Inc.
5.24+0.16
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
IMTX
Immatics N.V.
10.09+0.11
JANX
Janux Therapeutics, Inc.
14.65-0.47
MRUS
Merus N.V.
96.92+0.10
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
PDSB
PDS Biotechnology Corporation
0.90-0.02
VIRX
Viracta Therapeutics, Inc.
0.01+0.00